Skip to main content
VCbacked
Log inGet Started

Kailera Therapeutics

Waltham, United States

Kailera Therapeutics develops next-generation injectable and oral therapies for chronic weight management.

$600.0M raised
Oct 2025
Series B
BiotechnologyPharmaceuticalTherapeutics

Top Investors

Janus Henderson InvestorsAdage Capital ManagementRTW InvestmentsT. Rowe PriceAtlas Venture

Founder Contacts

19,000+ verified contacts
Get Instant Access

Emails, phones & LinkedIn profiles

Frequently Asked Questions about Kailera Therapeutics

How much funding has Kailera Therapeutics raised?
Kailera Therapeutics has raised $600.0M in total funding. The most recent round was Series B. The last funding was announced in October 2025.
Who are Kailera Therapeutics's investors?
Kailera Therapeutics's investors include Janus Henderson Investors, Adage Capital Management, RTW Investments, T. Rowe Price, Atlas Venture.
Where is Kailera Therapeutics headquartered?
Kailera Therapeutics is headquartered in Waltham, United States.
What does Kailera Therapeutics do?
Kailera Therapeutics develops next-generation injectable and oral therapies for chronic weight management.
What stage is Kailera Therapeutics at?
Kailera Therapeutics is at the Series B stage.
Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .

MLA
"Kailera Therapeutics — Funding & Investors." VCBacked, October 14, 2025, https://www.vcbacked.co/company/kailera-therapeutics. Accessed June 9, 2026.
APA
VCBacked. (2025). Kailera Therapeutics — Funding & Investors. Retrieved June 9, 2026, from https://www.vcbacked.co/company/kailera-therapeutics
Wikipedia (cite web)
{{cite web |title=Kailera Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/kailera-therapeutics |website=VCBacked |access-date=June 9, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated .

Similar Companies in Biotechnology

View all
Virtuoso Surgical
Nashville
Pharvaris
Zug
Odyssey Therapeutics
Boston$213.0M
Tempus
Chicago
Anagram Therapeutics
Boston
Prenetics
Hong Kong